# An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

> **NCT06590480** · — · NO_LONGER_AVAILABLE · sponsor: **Replimune, Inc.**

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** RP1
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT06590480
- **Lead sponsor:** Replimune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590480, "An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06590480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*